Mark Rogers

3.2k total citations
57 papers, 2.6k citations indexed

About

Mark Rogers is a scholar working on Molecular Biology, Neurology and Nutrition and Dietetics. According to data from OpenAlex, Mark Rogers has authored 57 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 13 papers in Neurology and 9 papers in Nutrition and Dietetics. Recurrent topics in Mark Rogers's work include Prion Diseases and Protein Misfolding (22 papers), Neurological diseases and metabolism (12 papers) and Trace Elements in Health (7 papers). Mark Rogers is often cited by papers focused on Prion Diseases and Protein Misfolding (22 papers), Neurological diseases and metabolism (12 papers) and Trace Elements in Health (7 papers). Mark Rogers collaborates with scholars based in Ireland, United States and United Kingdom. Mark Rogers's co-authors include Stanley B. Prusiner, Michael Scott, Fruma Yehiely, Karen S. Moore, Suzanne Wehrli, J. N. Forrest, Donald R. McCrimmon, Heinrich Röder, M Zasloff and Robert M. Glickman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Neuron and Journal of Clinical Oncology.

In The Last Decade

Mark Rogers

56 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Rogers Ireland 29 1.7k 661 510 270 172 57 2.6k
Jeanne Grosclaude France 30 1.9k 1.1× 507 0.8× 688 1.3× 386 1.4× 125 0.7× 66 2.9k
Brent Race United States 32 2.4k 1.4× 1.2k 1.7× 643 1.3× 195 0.7× 105 0.6× 87 3.1k
Motohiro Horiuchi Japan 31 2.4k 1.4× 1.1k 1.7× 992 1.9× 346 1.3× 152 0.9× 143 3.3k
Juan María Torres Spain 34 2.6k 1.5× 1.1k 1.7× 801 1.6× 289 1.1× 147 0.9× 155 3.3k
Bruno P. Meloni Australia 37 1.4k 0.8× 408 0.6× 92 0.2× 925 3.4× 384 2.2× 122 4.1k
Marek Wieczorek Poland 22 672 0.4× 126 0.2× 53 0.1× 112 0.4× 200 1.2× 74 2.0k
Christopher R. Birkett United Kingdom 14 2.4k 1.4× 978 1.5× 707 1.4× 63 0.2× 68 0.4× 22 2.6k
Chantal Cazevieille France 25 847 0.5× 102 0.2× 89 0.2× 99 0.4× 360 2.1× 56 2.3k
Hermann Schätzl Germany 35 3.5k 2.1× 1.4k 2.1× 1.1k 2.2× 296 1.1× 666 3.9× 133 4.6k
Johanna Chluba France 23 1.0k 0.6× 54 0.1× 126 0.2× 52 0.2× 102 0.6× 38 2.9k

Countries citing papers authored by Mark Rogers

Since Specialization
Citations

This map shows the geographic impact of Mark Rogers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Rogers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Rogers more than expected).

Fields of papers citing papers by Mark Rogers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Rogers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Rogers. The network helps show where Mark Rogers may publish in the future.

Co-authorship network of co-authors of Mark Rogers

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Rogers. A scholar is included among the top collaborators of Mark Rogers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Rogers. Mark Rogers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pitson, Graham, et al.. (2019). MA19.11 Population Based Analysis of End of Life Treatment Patterns in Thoracic Malignancies. Journal of Thoracic Oncology. 14(10). S329–S330. 1 indexed citations
2.
Wood, Libby, Isabell Cordts, António Atalaia, et al.. (2017). The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research. Journal of Neurology. 264(5). 979–988. 21 indexed citations
3.
McCarthy, J. Michael, Markus Franke, Jeremy C. Simpson, et al.. (2013). Anti-Prion Drug mPPIg5 Inhibits PrPC Conversion to PrPSc. PLoS ONE. 8(1). e55282–e55282. 25 indexed citations
4.
McCarthy, J. Michael, Dietmar Appelhans, Jörg Tatzelt, & Mark Rogers. (2013). Nanomedicine for prion disease treatment. Prion. 7(3). 198–202. 19 indexed citations
5.
McCarthy, J. Michael, et al.. (2012). Differentiating Prion Strains Using Dendrimers. Advanced Healthcare Materials. 1(6). 768–772. 19 indexed citations
6.
Hilton‐Jones, David, Cheryl Longman, Richard Petty, et al.. (2012). Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1 – The patients’ perspective. Neuromuscular Disorders. 22(7). 597–603. 25 indexed citations
7.
Forde, Niamh, Mark Rogers, M.J. Canty, et al.. (2007). Association of the prion protein and its expression with ovarian follicle development in cattle. Molecular Reproduction and Development. 75(2). 243–249. 15 indexed citations
8.
Bandyopadhyay, Sanghamitra, Jake Ni, Mark Rogers, et al.. (2006). A High-Throughput Drug Screen Targeted to the 5′Untranslated Region of Alzheimer Amyloid Precursor Protein mRNA. SLAS DISCOVERY. 11(5). 469–480. 30 indexed citations
9.
Pichon, Bruno, Mark Rogers, Damian Egan, & Jeremy Gray. (2005). Blood-Meal Analysis for the Identification of Reservoir Hosts of Tick-Borne Pathogens in Ireland. Vector-Borne and Zoonotic Diseases. 5(2). 172–180. 67 indexed citations
10.
Gutiérrez‐Adán, Alfonso, Alejandro Brun, Belén Pintado, et al.. (2003). Early detection of PrP res in BSE-infected bovine PrP transgenic mice. Archives of Virology. 148(4). 677–691. 103 indexed citations
11.
Harper, Peter S., et al.. (2002). 99th ENMC international workshop: myotonic dystrophy: present management, future therapy. Neuromuscular Disorders. 12(6). 596–599. 37 indexed citations
12.
Rogers, Mark, et al.. (2001). INTERFERON GAMMA AND PROSTAGLANDIN IN BSE-INFECTED CATTLE. Cytokine. 13(3). 169–173. 6 indexed citations
13.
Rogers, Mark, et al.. (1998). A new mechanism broadening the role of prion proteins in neurodegeneration. Trends in Genetics. 14(5). 171–173. 3 indexed citations
14.
O’Boyle, Kathy M., et al.. (1998). Functional coupling of a recombinant Human 5‐HT5A receptor to G‐proteins in HEK‐293 cells. British Journal of Pharmacology. 124(6). 1238–1244. 31 indexed citations
15.
Loftus, Brendan & Mark Rogers. (1997). Characterization of a prion protein (PrP) gene from rabbit; a species with apparent resistance to infection by prions. Gene. 184(2). 215–219. 25 indexed citations
16.
Flavin, N., Luís V. Monteagudo, Sean Ennis, et al.. (1996). Cloning of the bovine activin receptor type II gene (ACVR2) and mapping to chromosome 2 (BTA2). Cytogenetic and Genome Research. 75(1). 25–29. 32 indexed citations
17.
Monteagudo, Luís V., et al.. (1996). Fluorescent in situ localization of the bovine Activin receptor type IIA locus on Chromosome 2 (2q2.3-2.4). Mammalian Genome. 7(11). 869–869. 1 indexed citations
18.
Hughes, M S, S.D. Neill, & Mark Rogers. (1996). Vaccination of the badger (Meles meles) against Mycobacterium bovis. Veterinary Microbiology. 51(3-4). 363–379. 25 indexed citations
19.
Borchelt, David, Mark Rogers, Neil Stahl, Glenn C. Telling, & Stanley B. Prusiner. (1993). Release of the cellular prion protein from cultured cells after loss of its glycoinositol phospholipid anchor. Glycobiology. 3(4). 319–329. 107 indexed citations
20.
Rogers, Mark, W. H. Atkinson, & Donald N. O'Connell. (1959). Sweetness and saltiness of compound solutions of sucrose and NaCl as a function of concentration of solutes.. Journal of Experimental Psychology. 57(4). 231–234. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeanne Grosclaude Breakdown of academic impact, for papers by Brent Race Breakdown of academic impact, for papers by Motohiro Horiuchi Breakdown of academic impact, for papers by Juan María Torres Breakdown of academic impact, for papers by Bruno P. Meloni Breakdown of academic impact, for papers by Marek Wieczorek Breakdown of academic impact, for papers by Christopher R. Birkett Breakdown of academic impact, for papers by Chantal Cazevieille Breakdown of academic impact, for papers by Hermann Schätzl Breakdown of academic impact, for papers by Johanna Chluba
Rankless by CCL
2026